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Abstract
Background: Searches for differentially expressed genes in tumours have made extensive use of
array technology. Most samples have been obtained from tumour biopsies or from established
tumour-derived cell lines. Here we compare cultures of non-immortalized breast cancer cells,
normal non-immortalized breast cells and immortalized normal and breast cancer cells to identify
which elements of a defined set of well-known cancer-related genes are differentially expressed.
Methods: Cultures of cells from pleural effusions or ascitic fluids from breast cancer patients
(MSSMs) were used in addition to commercially-available normal breast epithelial cells (HMECs),
established breast cancer cell lines (T-est) and established normal breast cells (N-est). The Atlas
Human Cancer 1.2 cDNA expression array was employed. The data obtained were analysed using
widely-available statistical and clustering software and further validated through real-time PCR.
Results: According to Significance Analysis of Microarray (SAM) and AtlasImage software, 48
genes differed at least 2-fold in adjusted intensities between HMECs and MSSMs (p < 0.01). Some
of these genes have already been directly linked with breast cancer, metastasis and malignant
progression, whilst others encode receptors linked to signal transduction pathways or are
otherwise related to cell proliferation. Fifty genes showed at least a 2.5-fold difference between
MSSMs and T-est cells according to AtlasImage, 2-fold according to SAM. Most of these classified
as genes related to metabolism and cell communication.
Conclusion: The expression profiles of 1176 genes were determined in finite life-span cultures of
metastatic breast cancer cells and of normal breast cells. Significant differences were detected
between the finite life-span breast cancer cell cultures and the established breast cancer cell lines.
These data suggest caution in extrapolating information from established lines for application to
clinical cancer research.
Background
The search for differentially expressed genes in tumours
has made extensive use of array technology. Most studies
have involved tumour biopsy samples or established
tumour-derived cell lines [1]. Differentially expressed
genes may help to identify tumours with high metastatic
potential and pathways that might be therapeutic targets.
As noted by Dairkee et al. [2], one drawback of using
established cell lines is that the process of immortaliza-
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tion in vitro can bias the expression profile when com-
pared to native tissues. Another problem is that a number
of widely-used cell lines have sub-lines that differ in their
karyotypes and RNA expression levels [3-5]. Biopsies from
tumours, unless they are microdissected, contain hetero-
geneous cell types. A molecular signature (or expression
profile) of the whole tumour can be misleading since it is
a composite of all the cells, normal and malignant,
present in it. Although tumours may consist of several
populations of cells that deviate slightly from the clonal
strain of origin, metastases may involve only the sub-
line(s) with specific genetic changes that favour metastatic
behaviour. Cultures from freshly-derived ascites or pleural
effusions may therefore be relatively homogeneous before
they acquire the further mutations that immortalize cell
lines with unlimited growth potential.
In this communication we report which genes, within a
defined set of well-known cancer-related genes, are differ-
entially expressed in freshly-derived breast cancer cell cul-
tures compared with primary normal, established normal
and breast cancer cultures. We compared expression pat-
terns in cultures of finite life-span cells from pleural effu-
sions or ascites of breast cancer patients (Mount Sinai
School of Medicine: MSSM) with commercially-available
finite life-span normal breast epithelial cells (HMECs). To
ensure comparability, cultures were used at similar pas-
sage numbers and the karyotypes were analyzed. We also
compared the expression profiles of some of the most
widely-used established breast cancer cell lines and three
putatively normal established breast cell lines.
Methods
Cultures of finite life-span cells
a): HMECs: Different batches of normal human mam-
mary epithelial cells cultures were obtained (Biowhittaker
Molecular Applications Inc., NJ). HMEC specimens were
enumerated serially and maintained with MEGM (Clonet-
ics, MD) supplemented with 2.5% FCS (Gibco Invitrogen,
CA).
b): MSSMs: Breast cancer cells obtained from ascitic fluids
or pleural effusions of patients with breast cancer were
seeded and maintained in our laboratory. They were des-
ignated MSSM 3 through MSSM 14 and maintained in
MEGM supplemented with 2.5% of the corresponding
original fluid when available and 2.5% FCS (Gibco Invit-
rogen, CA). The full characterization of these cultures will
be published elsewhere (manuscript in preparation).
HMECs were passaged only twice or thrice in our labora-
tory. MSSMs were harvested at the 5th or 6th passage after
initial plating.
Cultures of established cell lines
a): Normal-established (N-est.): the cell lines used were
derived from normal tissues: MTSV1-7 (a gift from J. Tay-
lor-Papadimitriou), MCF10A (from R Mira y Lopez) and
MCF10F (ATCC, MD).
b): Tumour-established (T-est.): cell lines established
from breast cancer pleural effusions or tumour tissues:
MDA-MB231, MDA-MB453, MDA-MB468, two strains of
MCF 7 (designated MCF 7N and MCF 7P), T47D, BT20
and BT474 (all from ATCC, MD). They were maintained
in medium and supplements as recommended by ATCC.
All cell cultures were harvested 48–72 h after plating at
about 80% confluence. Sources and markers are given in
Table 1.
Arrays
The Atlas Human Cancer 1.2 cDNA expression array
(Clontech, CA) is a nylon membrane printed with 200–
600 bp fragments of 1176 characterized genes involved in
cancer, 9 housekeeping genes and 6 negative controls.
RNAs were extracted and labelled with the Atlas pure total
RNA labelling system and hybridized according to the
manufacturer's instructions.
All the cell lines used for the arrays (9 HMECs, 10 MSSMs,
3 N-est and 7 T-est) were probed twice in separate assays.
The accuracy of the duplicates was assessed by Pearson's
correlation coefficient based on the adjusted intensities of
all the genes spotted on the membrane, which ranged
from 0.93 to 0.99.
Hybridizations with 30 µg of total RNA were performed
according to the manufacturer's instructions. The hybrid-
ized membranes were exposed to a phosphorimager
screen and were read at 100 µm resolution in a Storm
Phosphorimaging system (Molecular Dynamics, CA). The
scanned images were transformed to TIFF files with a PC
bit order and then aligned and analyzed using AtlasImage
2.01 software (Clontech, CA). To average or compare the
samples, the adjusted intensity signal was normalized
using the global normalization mode featured in the soft-
ware. We report only (a) those genes with significant (p <
0.01) differential expression of 2-fold or more, and (b)
genes that were undefined for all the cell lines belonging
to one type of sample, but were detected in other types
with a difference at least equivalent to one background
(540 units in intensity). (Undefined genes are those for
which the intensity was below the signal threshold).
The AtlasImage software compares only two samples at a
time. When we used it to determine the differences
between cell classes, we first averaged the cell lines in the
four classes (HMEC, MSSM, N-est and T-est) and then per-BMC Cancer 2006, 6:99 http://www.biomedcentral.com/1471-2407/6/99
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formed the comparisons as instructed by the manufac-
turer.
Statistical analyses (correlation and two-tailed p values)
were performed using Microsoft Excel 2000. Further anal-
yses were performed with Significance Analysis of Micro-
arrays (SAM) [6], Prediction Analysis for Microarrays
(PAM) (Stanford Univ., USA), FatiGO [7], Pomelo tool
and SVM (Bioinformatics unit, CNIO, Spain [8]) and
GoMiner [9].
Quantitative real-time PCR (Q-PCR)
To validate the results of the cDNA array experiments,
some of the genes found to be differentially expressed
were further examined by real-time PCR in 10 HMECs, 9
MSSMs, 3 N-est and 8 T-est cell lines. Five µg of total RNA
(corresponding to about 100 ng of mRNA) were reverse-
transcribed with oligo(dT) (SuperScript II system, Invitro-
gen, CA) in a 20 µl reaction volume, and after 125-fold
dilution, 1.25 µl were used for a 40-cycle PCR on an ABI
Prism 7900 thermal cycler. The reaction was carried out in
a 384-well plate with a QuantiTect SYBR Green PCR kit
(Qiagen Inc, CA) at an annealing temperature of 63°C
and detection at 2–5°C below the Tm of the product as
determined from its dissociation curve. Product size was
confirmed by agarose gel electrophoresis. The efficiency of
each pair of primers for amplification was determined and
expression of each gene relative to G3PDH was assessed
by the program Qgene [10]. Primers were designed using
the program PrimerQuest or Primer3, unless otherwise
stated. Primer sequences, lengths and Tms of the products
are given in Additional file 4.
Table 1: Cell origin and RNA expression of some frequently used markers
cell line origin (a) KT14 KT18 Vim ER ERBB2 ERBB3 MGB1 MGB2
HMEC #1 mammary epithelial + + ++ +/- + + +/- +
HMEC #2 mammary epithelial + + + ND ND ND ND ND
HMEC #3 mammary epithelial ND ND ND - + + - +
HMEC #6 mammary epithelial + + ++ - + + - +
HMEC #7 mammary epithelial + + ++ +/- + + - +
HMEC #8 mammary epithelial ND ND ND +/- + + + +
HMEC #9 mammary epithelial + + ++ + + + + +
HMEC #10 mammary epithelial + + ++ +/- + + + +
HMEC #11 mammary epithelial + + ++ + + + - +
HMEC #12 mammary epithelial + + + + + + - +
HMEC #13 mammary epithelial + + + - + + - +
MSSM 3 ascites - + ++ + + +/- - -
MSSM 4 pleural effusion - + ++ - + - - +
MSSM 5 pleural effusion - + ++ + + +/- - +
MSSM 6 pleural effusion - + ++ +/- + + - +
MSSM 7 pleural effusion + + ++ - + - + -
MSSM 8 pleural effusion - + ++ +/- + + + +
MSSM 9 ascites - + ++ +/- + - + +
MSSM 10 pleural effusion - + ++ - + +/- + +
MSSM 11 pleural effusion - + ++ +/- + + + +
MSSM 14 ascites - + ++ +/- + - + +
MTSV1-7 from milk - + ++ - + +/- - -
MCF 10A mammary gland, adherent + + ++ +/- + + + +
MCF 10F mammary gland, floating + + +/- + + + - +
MDA-MB 231 pleural effusion - + ++ - + + - +
MDA-MB 453 effusion - + + - + (c) +++
MDA-MB 468 pleural effusion + + + - + + + -
MCF 7 N pleural effusion - + +/- + + + - +
MCF 7 P pleural effusion - + + + + + + +
T47D pleural effusion - + - + + + + +
BT20 prim tumor + + +/- + (b) +++ +
BT474 invasive ductal carc ND ND ND - + ND + +
Determination of the presence of mRNA for the KT and VIM markers shows the results of the array experiment. Determination for the receptors 
was done in triplicate by RT-PCR. +/-: 1/3 show the specific product of the PCR, -: none of the three, +: all of them, ND: not done.
(a) HMECs and established cell lines according to the providers (Clonetics, ATCC).
(b) It is known that BT20 transcribes an mRNA for this gene with a deletion in the fifth exon and hence the cell does not express the protein 
(ATCC).
(c) MDA-MB 453 showed a 27.2 fold up-regulation when compared to the HMECs (29.3 with MCF 10A), consistent with its amplified ERBB2 gene.BMC Cancer 2006, 6:99 http://www.biomedcentral.com/1471-2407/6/99
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Samples were tested twice in triplicate. Pearson correla-
tion coefficients for the duplicate Q-PCR results ranged
between 0.89 and 0.99.
Results
Overall gene expression and class prediction
All the MSSM cultures displayed similar growth rates and
had no or minimal chromosomal changes (data not
shown). Table 1 shows the main characteristics of these
cells.
Each cell line was probed twice. Averages of the duplicates
after normalization of the adjusted intensities (as
described in the Atlas manual and briefly in Materials and
Methods) were used to obtain the expression values for
further analysis. The overall gene expression profile, as
determined by Pearson's correlation coefficient, discrimi-
nates between HMECs and cells derived from metastasis
of breast cancer (MSSMs). As seen in Table 2 (and detailed
in Additional file 1) the correlation within cell classes was
> 0.90; the correlation between cell classes was < 0.82.
Hybridization signals of 928 genes (78.9%) were repre-
sented in at least three cell lines. (One class, N-est, com-
prised three cell lines; the other three classes, HMEC,
MSSM and T-est, comprised more.) We used this subset of
928 genes, plus the 9 control genes, to construct a classifi-
cation model using two prediction programs: PAM and
SVM. Since these algorithms do not work well when the
numbers of members differ among classes, we trained the
SVM program using comparable numbers of lines from
three classes (8 HMECs, 9 MSSMs and 7 T-est) and treated
the three N-est cell lines and the remaining HMECs and
MSSMs as unknowns to be classified. The model thus gen-
erated had a classification accuracy of 100% (24/24) by
the leave-one-out cross-validation method. The predic-
tion for the three N-est lines was T-est, suggesting that
these cells have an expression profile resembling those of
the other established cell lines rather than the cultures of
finite life-span cells. The remaining HMEC and MSSM cell
cultures were correctly assigned to their respective classes
(see Additional file 5).
The same analysis with PAM, applying a threshold of 3.5,
which gives the maximum number of significant genes
yielding no misclassification error upon cross-validation,
predicted MTSV1-7 and MCF 10F as members of the "T-
est" class and MCF 10A as an HMEC-class member with a
probability of 1. Again, HMEC 13 and MSSM 14 were
properly assigned (Fig 1 and Additional file 2). Further to
elucidate the classification of MCF10A, which is the most
widely-used putatively normal breast cell line in array
analysis, we examined the expression values of KT14,
KT8/18 and KT19 (Fig. 2A and 2B) and CD104. The
MCF10A values were similar to those of the HMECs.
Comparison of non-immortalized normal and cancer 
breast cells
Of the 1176 genes in the array, 862 (73.3%) gave hybrid-
ization signals in at least three of the finite life-span cell
lines used. Of these, 123 (14.3%) showed differential
expression when HMEC and MSSM cells were analyzed
using the AtlasImage software (ratio >2 and difference in
adjusted intensity > 540), and 101 were deemed signifi-
cant genes with SAM (q-value: 0.7298, median #FDR:
0.73718) (Additional file 6).
Of these 123 from Atlas and 101 from SAM, 75 genes were
differentially expressed with at least a 2-fold change
according to SAM and AtlasImage, a minimum difference
in intensity of 540 units and a p-value < 0.01 (Excel).
These two programs use different algorithms to calculate
the ratio (AtlasImage) and fold (SAM) values, so the out-
puts are not exactly the same. Fig. 3 shows the relative
expressions of these 75 genes in all the cell lines analyzed
by the arrays using the software Pomelo Tool (FDR and p-
values for each gene in Additional file 7).
Some genes showed a broad range of expression values
among cell lines belonging to the same group: one or two
individual cell lines over-expressed the gene (>5 fold the
average of the cell class), while others in the same class
gave no signal or were barely above background. Since we
were looking for genes that could enable us to differenti-
ate among types of cell lines, and hence be useful as mark-
ers for each class, we inspected the values of these genes
manually. The aim was to exclude from the 75 genes in Fig
3 any that gave extreme values in 2 or more cell lines
within a class; "extreme values" were those that lay in the
range of the other class, or biased the average of the class
in question to generate the required 2-fold change.
Twenty seven up-regulated and 21 down-regulated genes
remained, in addition to the cytokeratins, which are not
included in Tables 3 and 4 but shown in Fig 2. Their dis-
Table 2: Correlation between cell lines.
median range
Intragroup HMECs 0.91 0.83–0.96
MSSMs 0.94 0.81–0.97
Normal-est 0.82 0.80–0.88
Tumour-est 0.85 0.78–0.95
Intergroup HMECs vs MSSMs 0.74 0.61–0.82
HMECs vs Normal-est 0.85 0.69–0.93
HMECs vs Tumour-est 0.77 0.67–0.85
MSSMs vs Normal-est 0.77 0.68–0.87
MSSMs vs Tumour-est 0.75 0.64–0.84
Normal-est vs Tumour-est 0.82 0.77–0.88
Significance of HMECs or MSSMs to HMECs vs MSSMs by Wilcoxon-
Mann-Whitney test two-sided, p value = p < 0.0001BMC Cancer 2006, 6:99 http://www.biomedcentral.com/1471-2407/6/99
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PAM (Prediction Analysis of Microarrays) Figure 1
PAM (Prediction Analysis of Microarrays). This is a statistical technique for class prediction from gene expression data 
using nearest shrunken centroids. This method identifies the subsets of genes that best characterize each class. a) Plot of the 
shrunkencentroids for the specified threshold with the ranked list of significant genes that are used for the predictions. b) Pre-
diction and probabilities of the test cell lines (MTSV1-7, MCF10A, MCF10F, HMEC 13 and MSSM 14).
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Expression of KT14, KT18 and KT19 Figure 2
Expression of KT14, KT18 and KT19. a) Plot showsthe correlation of the adjusted intensity (AI) signal of the pair KT8/
KT18 for each cell line. b) AI of KT14, KT18 and KT19 of each cell line and its relative percentage.
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KT14 KT18 KT19       
  J00124  M26326  Y00503    % K14  % K18  % K19 
HMEC 1  27441.73  1266.48 0.00  95.59 4.41  0.00 
HMEC 2  31925.09 2131.99  278.40  92.98  6.21  0.81 
HMEC 6  25589.53 2816.90  264.82  89.25  9.82  0.92 
HMEC 7  19657.96 1769.78  449.32  89.86  8.09  2.05 
HMEC 9  26914.59 1879.09  669.62  91.35  6.38  2.27 
HMEC 10  23949.08  2329.77 0.00  91.13 8.87  0.00 
HMEC 11  38597.37  1813.07 0.00  95.51 4.49  0.00 
HMEC 12  40845.17 3181.96  758.19  91.20  7.10  1.69 
HMEC 13  31802.26  3020.48 0.00  91.33 8.67  0.00 
MSSM 3   0.00 7827.06  5594.77  0.00 58.32  41.68 
MSSM 4  0.00 3786.02  3731.15  0.00 50.36  49.64 
MSSM 5  0.00 6999.72  3987.50  0.00 63.71  36.29 
MSSM 6  0.00 9143.63  5257.12  0.00 63.49  36.51 
MSSM 7  1023.43  4518.62  4436.78  10.26 45.28 44.46 
MSSM 8  0.00 6033.20  4634.70  0.00 56.55  43.45 
MSSM 9  0.00 9893.13  6055.28  0.00 62.03  37.97 
MSSM 10  0.00 8983.98  8535.09  0.00 51.28  48.72 
MSSM 11  0.00 7945.49  4572.03  0.00 63.47  36.53 
MSSM 14  0.00 8542.60  4066.33  0.00 67.75  32.25 
MTSV1-7  0.00 7008.82  803.44  0.00 89.72  10.28 
MCF 10A  18237.66  1788.84 0.00  91.07 8.93  0.00 
MCF 10F  14645.68  6765.23 0.00  68.40  31.60 0.00 
MDA 231  0.00 3444.53  3308.57    0.00 51.01  48.99 
MDA468  10598.28  5546.68  9313.11    41.63 21.79 36.58 
MDA453  0.00 11114.15  8401.00    0.00  56.95 43.05 
MCF7-  0.00 27023.79  17343.81    0.00  60.91 39.09 
MCF7+  0.00 20883.18  13194.28    0.00  61.28 38.72 
T47D  0.00 12020.16  16114.47    0.00  42.72 57.28 
BT20  3380.41 12285.95 3613.03   17.53  63.73  18.74 BMC Cancer 2006, 6:99 http://www.biomedcentral.com/1471-2407/6/99
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Relative expression of all the 29 cell linestested by Atlas arrays Figure 3
Relative expression of all the 29 cell linestested by Atlas arrays. Output of the Pomelo tool showing the log2 of the 
relative expression of the selected genes in each cell line to the average expression of all the cell lines. The 75 genes shown 
here were considered differentially expressed by SAM and by AtlasImage, with at least a 2-fold change for both programs, 
when we compared the HMEC and MSSM cell classes.BMC Cancer 2006, 6:99 http://www.biomedcentral.com/1471-2407/6/99
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Table 3: Gene expression of MSSM cells in relation to HMEC cells Up regulated Genes in MSSM cells
SAM t-test Atlas
Name Score(d) Fold p value Ratio Diff Protein/gene Gene ontology
IGFBP4 9.7872 57.60 2.15E-07 47.46 5296 insulin-like growth factor binding 
protein 4
cell communication
cellular physiological process
metabolism
morphogenesis
regulation of cellular process
FES 8.9172 37.10 1.13E-10 31.76 1292 C-fes proto-oncogene cell communication
cellular physiological process
metabolism
LAMA4 7.8262 159.92 2.95E-12 131.73 3399 laminin alpha 4 subunit cell communication
cellular physiological process
regulation of cellular process
FCGRT 7.4658 6.22 1.43E-03 5.18 3425 IgG receptor FC large subunit P51 response to stimulus
FGFR1 7.3244 1925.86 7.01E-12 Up 2368 N-sam; fibroblast growth factor 
receptor1
cell communication
metabolism
morphogenesis
MMP11 6.7459 4.79 4.30E-08 4.67 29606 matrix metalloproteinase 11; 
stromelysin 3
metabolism
morphogenesis
TIMP1 6.3100 4.22 3.66E-07 4.15 30855 metalloproteinase inhibitor 1 cellular physiological process
metabolism
regulation of cellular process
TIMP2 6.3100 4.22 6.14E-04 5.64 1713 tissue inhibitor of metalloproteinases 
2
cellular physiological process
PTPRS 6.2185 11.57 5.03E-05 12.56 705 protein tyrosine phosphatase sigma cell communication
metabolism
TGFBI 6.0130 3.99 1.71E-06 4.05 6759 BIGH3 cell communication
cellular physiological process
regulation of cellular process
response to stimulus
ITGB3 5.5711 71.88 6.47E-09 57.56 1527 integrin beta 3; CD61 antigen cell communication
TCIRG1 5.3497 15.08 9.83E-05 14.66 1257 specific 116-kDa vacuolar proton 
pump
cellular physiological process
regulation of cellular process
response to stimulus
TNFRSF1A 5.3392 2.97 2.29E-06 2.90 1875 tumor necrosis factor receptor 1 cell communication
cellular physiological process
regulation of cellular process
MOX2 5.1746 42.04 3.61E-05 39.85 777 OX2 membrane glycoprotein Gen with GO but NOT at level 3 biological process
TP53I3 4.9520 6.53 8.84E-05 5.73 1225 PIG3 Gen with GO but NOT at level 3 biological process
BDNF 4.8902 24.15 7.48E-05 21.05 762 brain-derived neurotrophic factor morphogenesis
TYRO3 4.3661 3.23 9.88E-03 2.93 1425 tyrosine-protein kinase receptor tyro3 
precursor; rse; sky; dtk
cell communication
metabolism
CTRL 4.2166 25.91 4.47E-05 19.65 1063 Chymotrypsin-like protease CTRL-1 metabolism
SPARC 4.1228 4.21 5.59E-04 4.30 2840 secreted protein acidic and rich in 
cysteine; osteonectin
morphogenesis
GPR4 3.8917 604.85 1.01E-05 Up 727 probable G protein-coupled receptor cell communication
DAB2 3.8635 8.91 1.48E-05 8.36 1339 mitogen-responsive phosphoprot. 
DOC2
cellular physiological process
COL6A1 3.7320 4.57 3.96E-04 4.44 3145 collagen 6 alpha 1 subunit cell communication
cellular physiological process
CDH2 3.7267 910.06 1.16E-05 Up 1162 N-cadherin; cadherin 2 cell communication
CTGF 3.7190 19.64 2.31E-05 17.28 1091 connective tissue growth factor cell communication
cellular physiological process
metabolism
morphogenesis
regulation of cellular process
response to stimulus
ITGA5 3.5646 3.49 2.47E-05 3.36 3815 integrin alpha 5 cell communication
regulation of cellular process
IGFBP5 3.4913 27.63 2.39E-04 21.90 1045 insulin-like growth factor binding 
protein 5
cell communication
cellular physiological process
morphogenesis
TNFRSF10D 3.2716 6.15 4.92E-04 5.25 1514 decoy receptor 2 cellular physiological processBMC Cancer 2006, 6:99 http://www.biomedcentral.com/1471-2407/6/99
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tribution according to GO (Gene Ontology) terms by
FatiGO at level 3 of biological processes is shown. These
changes in gene expression stress the importance in the
malignant process of both a diminished capacity for cell-
cell adhesion and the remodelling of the extracellular
matrix (ECM). For example: genes involved in adhesion
and downstream signalling (int α4/α6, P-cadherin
(CDH3), γ catenin (JUP)) or inhibitors of remodelling
(SPINT-2) were down-regulated, and ECM remodelling
enzymes (MMP11, TIMP2 and the cascade TIMP1-SPARC-
TGFBI) were up-regulated, as shown in Tables 3 and 4
(SVG file and p-values of GOMiner in Additional files 3
and 8 respectively).
Comparison of immortal and non-immortal breast cancer 
cells
Fifty genes showed significant >2-fold (according to SAM
software) and >2.5-fold (according to Atlas) differences
between the MSSMs and the established breast cancer cell
lines. Twenty-five were up-regulated and 25 down-regu-
Table 4: Gene expression of MSSM cells in relation to HMEC cells Down regulated Genes in MSSM cells.
SAM t-test Atlas
Name Score(d) Fold p value Ratio Diff Protein/gene Gene ontology
SFN -18.5106 -134.41 2.71E-08 -76.89 -14875 14-3-3 protein sigma; stratifin cell communication
cellular physiological process
metabolism
SPINT2 -14.6598 -37.30 4.10E-07 -39.72 -5653 bikunin; hepatocyte growth factor 
activator inhibitor 2
cellular physiological process
LAMB2 -11.3177 -12.53 8.94E-06 -12.09 -5510 laminin beta 2 subunit precursor cell communication
ITGA7 -11.0881 -13.03 3.24E-05 -12.06 -12577 integrin alpha 7B precursor cell communication
cellular physiological process
morphogenesis
CDH3 -8.9105 -12.11 3.62E-05 -15.23 -4283 cadherin 3; P-cadherin cell communication
response to stimulus
PLAU -7.9173 -10.37 2.18E-05 -22.29 -2512 urokinase-type plasminogen activator cell communication
cellular physiological process
metabolism
response to stimulus
ITGB4 -7.9148 -22.09 2.86E-05 -20.11 -16722 integrin beta 4; CD104 antigen cell communication
TPBG -7.6578 -5.42 2.34E-04 -4.84 -1922 5T4 oncofetal antigen precursor cell communication
cellular physiological process
RPS6KA1 -7.5622 -3.37 5.64E-08 -3.21 -3450 ribosomal protein S6 kinase alpha1 cell communication
metabolism
EDG4 -7.2225 -4.69 6.71E-04 -4.45 -1208 G protein-coupled receptor cell communication
IRF6 -6.7854 -120.19 4.26E-11 137.08 -1905 interferon regulatory factor 6 metabolism
LITAF -6.7240 -3.73 1.49E-03 -3.53 -2311 PIG7 cell communication
metabolism
regulation of cellular process
SEMA3F -6.4547 -3.55 1.90E-04 -2.68 -1510 semaphorin Gen with GO but NOT at level 3 
biological process
NOTCH1 -6.0498 -2.95 7.96E-04 -2.86 -1883 neurogenic locus notch protein 
homolog 1
metabolism
response to stimulus
ITGA6 -5.9332 1052.63 6.90E-07 Down -1273 integrin alpha 6 precursor cell communication
cellular physiological process
DSP -5.9015 1190.48 8.57E-07 Down -1463 desmoplakin I & II morphogenesis
CDA -5.4364 -21.03 4.64E-07 -18.79 -3523 cytidine deaminase metabolism
JUP -5.3936 -6.77 9.66E-07 -6.47 -6165 junction plakoglobin; desmoplakin III cell communication
JAG2 -5.2949 -4.22 1.20E-03 -4.30 -1841 jagged2 cell communication
cellular physiological process
morphogenesis
regulation of cellular process
response to stimulus
SERPINB1 -4.8852 -6.11 1.38E-04 -5.46 -1960 leukocyte elastase inhibitor Gen with GO but NOT at level 3 
biological process
BTG2 -4.8636 -24.34 3.84E-05 -11.74 -752 btg protein precursor; NGF- inducible 
anti-proliferative protein PC3
cellular physiological process
metabolism
regulation of cellular process
response to stimulus
Genes ordered according to their SAM scores and distribution of the genes according the GO terms using FatiGoBMC Cancer 2006, 6:99 http://www.biomedcentral.com/1471-2407/6/99
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lated in the established breast cancer cell lines compared
to the finite life-span cultures. Most of the differentially
expressed genes can be classified under the GO terms
"metabolism" and "cell communication". In particular:
most of the down-regulated genes seem to be related to
remodelling of the extracellular matrix, cell adhesion and
receptor-linked signal transduction, while the up-regu-
lated genes are related to general signal transduction path-
ways and cell proliferation (Tables 5 and 6).
Real-time PCR
To validate the differences seen in the arrays, some genes
were tested by real time PCR. We selected several genes of
which the expression was significantly increased or
decreased, according to SAM and Atlas, for both the
MSSM/HMEC and T-est/MSSM comparisons: 14-3-3σ
(also called SFN), SPINT2, FES, SPARC, BIGH3 (or
TGFBI), TIMP1, TIMP2, MMP11 and DAB2. Also, we ana-
lyzed some genes that were deemed significant for only
Table 5: Gene expression of T-est cells in relation to MSSM cells 25 Significant Up-regulated Genes in T-est cells
SAM Atlas
Name Score(d) Fold Ratio Diff Protein/gene Gene ontology
SPINT2 9.3646 51.350 65.437 7668 bikunin; hepatocyte growth factor activator 
inhibitor 2
cellular physiological process
PSME1 7.7824 3.034 3.630 3419 interferon-gamma IEF SSP 5111 response to stimulus
SFN 6.5917 37.394 25.868 3954 14-3-3 protein sigma; stratifin cell communication
cellular physiological process
metabolism
JUP 6.2887 4.779 5.825 4405 junction plakoglobin; desmoplakin III cell communication
TFAP2C 6.0176 89.861 108.133 1607 transcription factor erf-1; AP2 gamma transc 
factor
cell communication
metabolism
SLC25A5 5.6914 2.028 2.512 4761 ADP/ATP carrier protein cellular physiological process
GSTZ1 5.5683 11.704 13.413 1986 glutathione transferase zeta 1 metabolism
TBRG4 5.4262 2.362 2.859 3099 cell cycle progression 2 protein (CPR2) Gen with GO but NOT at level 3 biological 
process
EDG4 5.3459 7.169 8.197 2044 G protein-coupled receptor EDG4 cell communication
RPS6KA1 5.0882 2.030 2.528 1933 ribosomal S6 kinase 1 cell communication
metabolism
CTSD 4.9896 3.430 4.120 6462 cathepsin D precursor metabolism
HDGF 4.8236 2.112 2.590 2185 hepatoma-derived growth factor cell communication
cellular physiological process
PCTK1 4.5911 2.202 2.648 2444 serine/threonine-protein kinase PCTAIRE 1 cellular physiological process
metabolism
LITAF 4.4875 3.318 3.923 2166 PIG7 cell communication
metabolism
regulation of cellular process
PTPN6 4.4289 15.939 12.218 1391 protein-tyrosine phosphatase1C cell communication
cellular physiological process
metabolism
RFC2 4.3235 2.469 2.800 2036 replication factor C 40-kDa subunit (RFC40) cellular physiological process
metabolism
RARG 4.3142 2.640 3.020 1085 retinoic acid receptor gamma 1 metabolism
ADRBK1 4.2331 3.963 4.121 1211 G protein-coupled receptor kinase 2 (GRK2) cell communication
metabolism
CKS1B 4.2166 3.370 4.301 3341 cyclin-dependent kinase regulatory subunit 1 Gen with GO but NOT at level 3 biological 
process
RPS21 4.1856 2.210 2.674 2531 ribosomal protein S21 metabolism
AURKB 4.1129 4.052 5.168 1980 aurora- & IPL1-like protein kinase1; ARK2 cellular physiological process
metabolism
PPP2R4 3.9781 3.481 4.068 2433 phosphotyrosyl phosphatase activator metabolism
FASN 3.6731 2.953 3.615 4590 fatty acid synthase metabolism
GDF15 3.6008 5.032 5.878 10268 macrophage inhibitory cytokine 1 (MIC1) Gen with GO but NOT at level 3 biological 
process
MAPK13 3.5903 5.374 6.228 1652 stress-activated protein kinase 4 (SAPK4) cell communication
cellular physiological process
metabolism
response to stimulus
Genes ordered according to their SAM scores and distribution of the genes according the GO terms using FatiGoBMC Cancer 2006, 6:99 http://www.biomedcentral.com/1471-2407/6/99
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Table 6: Gene expression of T-est cells in relation to MSSM cells 25 Significant Down-regulated Genes in T-est cells
SAM Atlas
Name Score(d) Fold Ratio Diff. Protein/gene Gene ontology
FES -7.9514 -1063.830 Down -1081 C-fes proto-oncogene cell communication
cellular physiological process
metabolism
VIM -7.0022 -5.070 -3.698 -9614 vimentin Gen with GO but NOT at level 3
biological process
TGFBI -6.6491 -22.619 -17.180 -6844 BIGH3 cell communication
cellular physiological process
regulation of cellular process
response to stimulus
BMP1 -6.5296 -12.975 -9.085 -1609 bone morphogenetic prot. 1+ procollagen 
C-proteinase
metabolism
MLH1 -6.4271 -9.043 -6.664 -1552 mutL protein homolog; DNA mismatch 
repair protein
cellular physiological process
metabolism
response to stimulus
LAMA4 -6.3501 -24.913 -19.264 -2630 laminin alpha 4 subunit precursor cell communication
MMP11 -6.2022 -6.609 -5.019 -24432 matrix metalloproteinase 11; stromelysin 3 metabolism
TIMP1 -6.1061 -6.355 -4.793 -26048 metalloproteinase inhibitor 1 cellular physiological process
metabolism
regulation of cellular process
PLXNA3 -5.9530 -3.489 -2.845 -2334 transmembrane protein sex precursor Gen with GO but NOT at level 3
biological process
TIMP2 -5.1069 -6.041 -4.092 -1274 tissue inhibitor of metalloproteinases 2 cellular physiological process
ITGB8 -5.0533 -12.188 -8.712 -2414 integrin beta 8 cell communication
ITGB3 -4.8610 -1282.051 Down -1259 integrin beta 3 cell communication
SPARC -4.7998 -2857.143 Down -2997 secreted protein acidic and rich in cysteine 
precursor; osteonectin
physiological process
FN1 -4.5334 -50.633 -34.784 -10608 fibronectin precursor cell communication
cellular physiological process
metabolism
response to stimulus
MMP9 -4.5288 -12.126 -7.859 -1365 matrix metalloproteinase 9 metabolism
HSPG2 -4.3027 -1149.425 Down -1164 heparan sulfate proteoglycan cell communication
MMP14 -4.0581 -5.566 -3.840 -2454 matrix metalloproteinase 14; MT- MMP1 metabolism
ITGA5 -3.9413 -11.151 -7.838 -3836 integrin alpha 5 cell communication
MT3 -3.9295 -7.365 -5.866 -9946 metallothionein-III cellular physiological process
metabolism
regulation of cellular process
response to stimulus
DAB2 -3.8058 -1190.476 Down -1232 mitogen-responsive phosphoprotein DOC2 cellular physiological process
SERPINB
2
-3.6797 -1818.182 Down -1773 placental plasminogen activator inhibitor 2 
(PAI-2); urokinase inhibitor
cellular physiological process
regulation of cellular process
IGFBP6 -3.6326 -12.402 -8.758 -1668 insulin-like growth factor binding protein 6 
precursor
cell communication
cellular physiological process
regulation of cellular process
COL6A1 -3.6304 -8.586 -6.311 -2767 collagen 6 alpha 1 subunit (COL6A1) cell communication
cellular physiological process
IL6 -3.4586 -10.628 -7.933 -2586 interleukin-6 precursor cell communication
cellular physiological process
regulation of cellular process
response to stimulus
LIF -3.4166 -5.400 -3.940 -1085 leukemia inhibitory factor precursor cell communication
cellular physiological process
regulation of cellular process
response to stimulus
Genes ordered according to their SAM scores and distribution of the genes according the GO terms using FatiGoBMC Cancer 2006, 6:99 http://www.biomedcentral.com/1471-2407/6/99
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one of the comparisons: NOTCH1, PLAU, CDA and
SERPINB2 (or PAI2), and a few genes that were non-sig-
nificant but somehow related to some of the aforemen-
tioned genes: tPA, PAI1, uPAR, DCK.
It has been reported that correlation between Q-PCR and
array data is highly variable [11]. It depends, in part, on
the sensitivity of arrays in detecting genes with low expres-
sion levels or saturation due to very high ones. The genes
we have tested showed correlations that ranged from
0.563 to 0.959. For the comparison between the normal
(HMEC) and the tumour (MSSM) finite life-span cultures,
the Q-PCR results for the manually curated genes (as
explained above) supported the findings of the arrays in
17/17 (100%) of cases. In the T-est/MSSM evaluation,
agreement between the two techniques was found in 15/
17 (88.2%) of the cases (Fig. 4 and data available upon
request).
One of the genes excluded from the HMEC/MSSM com-
parison was CYR61, which was tested by Q-PCR. Even
though the overall up-regulation value for this gene was
consistent (SAM: 3.53, Atlas: 3.48, Q-PCR: 3.29), its
expression levels crossed over to the values of the other
cell class in 4/17 cell lines, thus invalidating CYR61 as a
reliable marker by itself.
Relative expression of some genes validated byQ-PCR Figure 4
Relative expression of some genes validated byQ-PCR. a) Mean normalized expression (MNE) of SPARC. b) MNE of 
BIGH3 = TGBFI. c) MNE of PAI-1. d) MNE of NOTCH1 in HMECs and MSSMs cells. e) Relative expression, of MSSMs and 
established cell lines, toMCF10A. Note the difference between the two MCF7s. f) MNE of CYR61. g) MNE of DAB-2. For the 
complete list of validated genes, see Table S1.
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Discussion
Established breast cancer cell lines have been widely used
to study signal transduction pathways, test new pharma-
ceuticals and determine expression profiles that might
predict the metastatic capabilities of primary tumours. In
many cases MCF10A has been chosen as the "normal"
control, even though this cell line has been reported to
possess markers for both myoepithelial and luminal phe-
notypes [12].
One of the controversies about the use of HMECs as con-
trols is the probable myoepithelial origin of these cells
[13] based on expression of KT14 and CD104 (ITGB4)
[14,15]. The expression levels of these genes in the MCF10
cells were equivalent to those in the HMECs. Furthermore,
the prediction of PAM, based on the 58 genes that dis-
criminate between the different classes of cells used in this
study, was that MCF10A was similar to HMECs. Hence,
MCF10A cells would have the same limitation as controls
as the HMECs. Nevertheless, HMEC cells have the advan-
tage of not being immortalized and pooling them com-
bines the genetic backgrounds of a large cohort.
Both classes of non-immortalized cell lines, HMEC and
MSSM, are more homogeneous than the established ones
(N-est and T-est), as seen in Table 2 and Additional file 1.
This is probably due to the cumulative effects of the muta-
tions accrued individually by the established cell lines
during successive passages and immortalization.
As seen in Fig 3, the expression of some genes in a partic-
ular class is clearly different from the others, e.g. up-regu-
lation of FES, MMP11, DAB2 and down-regulation of
SPINT2, SFN, JUP for the MSSM cells lines. Others are
more distinctive of a "state", e.g. distribution of cytokerat-
ins and down-regulation of certain integrins (ITGA6/
ITGB4, ITGA7) in all the tumour-derived cell lines. There-
fore, the expression levels of these genes can be seen as
specific attributes of certain classes. Their combined
expression defines a profile that can be used to construct
a model similar to those built by SVM and PAM for pre-
dicting the classification of an unknown cell line accu-
rately, as shown in fig 1B.
We tested only two sub-lines of MCF-7, well-known to be
highly variable [3-5], and a single sub-line of each of the
other established cell lines. We recognize that other sub-
lines might be different.
When the MSSMs are compared with the HMECs, several
genes display differential expression in a mode consistent
with previous publications, where they have been shown
to be significant for malignant progression or metastasis:
down-regulation of the tumour suppressor and inhibitor
of mitotic phase entry 14-3-3σ (SFN) [16,17], the serine
protease inhibitor SPINT2 [18] and JUP (γ-catenin) [19];
and up-regulation of FES [20] and SPARC [21]. In addi-
tion, there is the "cadherin switching" (CDH3 = P-cad-
herin to CDH2 = N-cadherin) and its relationship to
FGFR1 and MMP9 [22,23].
SPARC expression was detected in 17/17 human breast
tumour biopsies and to a lesser extent in some established
cell lines [21]. It has also been associated with malignant
progression and invasive potential in breast cancer
[24,25], and together with MMP11 in colorectal [26] and
oesophageal cancer [27]. Its over-expression increases
motility and invasion [28] and induces growth inhibition
[29] in established breast cancer cell lines. In addition, it
has been shown to induce expression of BIGH3 and PAI-
1[30]. MSSM cells showed up-regulation of SPARC,
BIGH3, PAI1 and MMP11, while the T-est cells showed
down-regulation of SPARC, BIGH3 and PAI1 (MDA-
MB231 is an exception for the latter gene) (Fig 4A-B-C).
We also found genes of which the behaviour did not fully
agree with previous descriptions, i.e. NOTCH1, CYR61
and DAB2. The many and varied functions of Notch sig-
nalling, achieved through activation or down-regulation,
have been recently reviewed [31]. In the MSSM samples,
NOTCH1 and its ligand JAG2 are down-regulated. In this
case, this pathway is more likely to function as a tumour
suppressor than an oncoprotein. This conclusion would
be less clear if we had only compared established cell lines
(mainly MCF10A with both MCF7s) (Fig 4D–E). CYR61 is
a pro-angiogenic, secreted protein encoded by a growth
factor-inducible immediate-early gene. It is over-
expressed in some invasive established breast cancer cell
lines and in 30–36% of primary tumours [32,33]. In this
study we found only three cell lines with a truly high over-
expression (MSSM6, MDA-MB231 and BT20) and five
with a moderate over-expression compared to the mean
expression in HMECs (between 2 and 4 fold). The same
conclusion would have applied if we had considered
MCF10A as a control (Fig 4F). DAB2 is considered a
tumour suppressor since its expression is down-regulated
in ovarian carcinomas and in some established breast can-
cer cell lines [34], and up-regulated during megakaryocyte
differentiation [35]. Its continued expression in tumour
cells led to growth inhibition or cell death [36] unless the
cells were in contact with some type of basement mem-
brane [37]. MSSM cells showed up-regulation of this gene
(Fig 4G), perhaps because they grew as an attached cell
line or because of their finite life-span phenotype in vitro.
Epithelial-mesenchymal transition (EMT) is considered a
mechanism for carcinoma progression and metastasis,
and the expression of vimentin (VIM) is its main marker.
This view has now been extended to include whole path-
ways and a more complex relationship with the microen-BMC Cancer 2006, 6:99 http://www.biomedcentral.com/1471-2407/6/99
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vironment of the cell [38,39]. Among the other genes
regulated during EMT [40], the MSSM cells showed up-
regulation of COL6A1, SPARC, CDH2 and DAB2 and
down-regulation of JUP and BTG2 (Tables 3 and 4).
Conclusion
Using arrays, we have studied 10 finite lifespan breast can-
cer cell lines freshly isolated from metastatic pleural or
peritoneal fluids, 9 finite lifespan normal breast cell lines,
7 established breast cancer cell lines, and 3 established
normal breast cell lines. We tested 1176 genes considered
to be related to cancer. Within each cell class there was sig-
nificant homogeneity of gene expression. Two clusters of
genes distinguished the MSSMs from the HMECs. These
48 genes, which were differentially expressed by at least 2
fold, concerned cell-cell interactions and remodelling of
the extracellular matrix. Fifty genes that were differentially
expressed at least 2 fold between MSSMs and established
breast cancer cell lines are generally considered to be
involved in cell communication and metabolism. Estab-
lished breast cancer cell lines have been used to model
biochemical and pharmacological responses in human
breast cancer; the differences from freshly isolated breast
cancer lines imply they are not wholly satisfactory models.
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